Literature DB >> 21336749

Outer membrane protein vesicle vaccines for meningococcal disease.

C E Frasch1, L van Alphen, J Holst, J T Poolman, E Rosenqvist.   

Abstract

Alternative strategies exist for prevention of group B Neisseria meningitidis (meningococcal) disease through vaccination (see Chapters 5 , 8 , 13 , 14 in this volume). However, the most promising approach to date has been the use of outer-membrane vesicle (OMV) vaccines for induction of bactericidal antibodies against cell-surface outer-membrane proteins (OMPs).

Entities:  

Year:  2001        PMID： 21336749     DOI： 10.1385/1-59259-148-5:81

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


  27 in total

1.  Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.

Authors:  Margaret Anne J Gidney; Joyce S Plested; Suzanne Lacelle; Philip A Coull; J Claire Wright; Katherine Makepeace; Jean-Robert Brisson; Andrew D Cox; E Richard Moxon; James C Richards
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

3.  Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.

Authors:  Jeannette N Williams; Paul J Skipp; Holly E Humphries; Myron Christodoulides; C David O'Connor; John E Heckels
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

4.  Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Authors:  Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff
Journal:  Vaccine       Date:  2011-05-13       Impact factor: 3.641

5.  Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Heather Stefek; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

6.  Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.

Authors:  Gregory R Moe; Patricia Zuno-Mitchell; Samantha N Hammond; Dan M Granoff
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection.

Authors:  John E Heckels; Jeannette N Williams
Journal:  Genome Med       Date:  2010-07-22       Impact factor: 11.117

8.  Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.

Authors:  V Weynants; P Denoël; N Devos; D Janssens; C Feron; K Goraj; P Momin; D Monnom; C Tans; A Vandercammen; F Wauters; Jan T Poolman
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

9.  Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.

Authors:  Oliver Koeberling; Serena Giuntini; Anja Seubert; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2008-12-24

10.  Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

Authors:  Vincent E Weynants; Christiane M Feron; Karine K Goraj; Martine P Bos; Philippe A Denoël; Vincent G Verlant; Jan Tommassen; Ian R A Peak; Ralph C Judd; Michael P Jennings; Jan T Poolman
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.